계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
SparingVision
company
About
SparingVision is a biotechnology company developing genomic medicines for the treatment of blinding inherited retinal diseases.
- 11 - 50
Details
- Last Funding Type
- Corporate Round
- Industries
- Biotechnology,Health Care,Life Science
- Founded date
- Jan 1, 2016
- Number Of Employee
- 11 - 50
- Operating Status
- Active
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
€119.50M
SparingVision has raised a total of
€119.50M
in funding over 2 rounds. Their latest funding was raised on
Sep 14, 2022 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 14, 2022 | Series B | €75M | 1 | — | — | Detail |
| Oct 13, 2021 | Corporate Round | — | 1 |
Intellia Therapeutics
|
— | Detail |
| Oct 21, 2020 | Series A | €44.50M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
SparingVision is funded by 3 investors.
Intellia Therapeutics
and Retinal Degeneration Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Intellia Therapeutics
|
Yes | Corporate Round |
Retinal Degeneration Fund
|
— | Series B |
Foundation Fighting Blindness
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
